trending Market Intelligence /marketintelligence/en/news-insights/trending/tayfs18Uw-ijQgeQ2I9W5w2 content esgSubNav
In This List

Report: After Johnson & Johnson, Sanofi in talks to acquire Actelion

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Report: After Johnson & Johnson, Sanofi in talks to acquire Actelion

Sanofi SA is in talks to acquire Actelion Pharmaceuticals Ltd. in a deal valued at up to $30 billion, The Wall Street Journal reported Dec. 13, citing sources.

The news follows Johnson & Johnson's decision to abandon a potential takeover of Actelion, which was asking for more than the U.S. pharma giant was willing to pay.

Johnson & Johnson's initial offer for Actelion was CHF246 per share, valuing the company at $26 billion, which Actelion rejected.

Actelion confirmed it was in talks with another party regarding a possible transaction following the Johnson & Johnson split. Sources say that party is Sanofi.

Sanofi reportedly aims to add Actelion's rare-disease drugs to its aging portfolio, which is losing patent protection.